Jennifer D. Twilla

Jennifer D. Twilla

Auto-generated profile, based on publicly available information

Jennifer D. Twilla

Methodist University Hospital, Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2016 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
EHEmily Higdon
Emily Higdon
JTJennifer D. Twilla
Jennifer D. Twilla
CSChristopher Sands
Christopher Sands
Fluoroquinolones are extensively used to treat a variety of common bacterial infections. Due to their extensive use in clinical practice, increases in neuropsychiatric events have been reported. We discuss the case of a young female who developed visual hallucinations after 2 doses of moxifloxacin. After discontinuation of the moxifloxacin, the patient’s symptoms completely resolved. While one other case report exists with moxifloxacin, this case is unique in comparison. Our patient was a young female with no kidney dysfunction, no drug abuse history, absence of polypharmacy, and no previous psychological history that would have put her at an increased risk of drug-induced psychosis. Due to the prevalence of medication-induced hallucinations, it is imperative that clinicians are able to recognize offending medications in an effort to prevent misdiagnosis of a psychiatric illness.

1 December 2019 in Alcohol
Verified
Journal Article
Closed access
KMKatherine L. March
Katherine L. March
JTJennifer D. Twilla
Jennifer D. Twilla
ARAnne B. Reaves
Anne B. Reaves
TSTimothy H. Self
Timothy H. Self
MSMelissa M. Slayton
Melissa M. Slayton
SSSami A. Sakaan
Sami A. Sakaan

13 February 2019 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
HRHeidi M. Riha
Heidi M. Riha
RWRachel Wilkinson
Rachel Wilkinson
JTJennifer Twilla
Jennifer Twilla
LHLeonard Harris
Leonard Harris
LKLauren A. Kimmons
Lauren A. Kimmons
MPMegan Van Berkel Patel
Megan Van Berkel Patel
Background: Literature indicating clinically relevant benefits of an adjunctive somatostatin analog to standard therapies in nonvariceal upper-gastrointestinal bleeding (NVUGIB) is lacking. Objective: The primary objective of this study was to find the association between outcomes in patients with NVUGIB treated with octreotide and a proton pump inhibitor (PPI; combination group) compared with those treated with a PPI alone. Methods: We conducted a retrospective cohort study of adults admitted within a 5-hospital health care system with a NVUGIB treated with a PPI continuous infusion with or without an octreotide infusion. Notable exclusion criteria included varices, history of cirrhosis without endoscopy, or active gastrointestinal cancer. The primary outcome was association of combination treatment versus PPI alone with hospital length of stay (LOS). Results: A total of 180 patients were included (combination group: n = 90; PPI: n = 90). In univariate analyses, the median hospital and intensive care unit (ICU) LOS in the combination group versus PPI was 6.1 versus 4.9 days (P = 0.25) and 2.3 versus 1.9 days (P = 0.24), and rebleeding and mortality occurred in 9% versus 12% (P = 0.63) and 6.7% versus 5.6% (P = 1.00) of patients. Median units of packed red blood cells in the combination therapy versus PPI group was 3 vs 2 units (P = 0.43). After propensity score adjustment in multivariable analyses, hospital and ICU LOS, rebleeding, and mortality all remained nonsignificant. Conclusion and Relevance: Our study observed no difference in clinical end points. This suggests that octreotide provides no additional major clinical benefit in NVUGIB, and PPI therapy alone may be sufficient.

21 March 2016 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
NRNeil Roe
Neil Roe
JTJennifer D Twilla
Jennifer D Twilla
BDBenjamin Duhart
Benjamin Duhart
BWBrian Wheeler
Brian Wheeler
Background: The development of angioedema is a rare yet serious clinical event that may develop due to an adverse drug reaction. Rapid recognition and treatment of this adverse reaction is critical for optimal patient outcomes; however, prevention of this occurrence is preferred. Case report: A 59-year-old woman presented to the emergency department with lingual angioedema caused by the addition of everolimus to her medication regimen. The patient improved after withdrawal of the offending agent and standard treatment. Early recognition by healthcare providers and management of everolimus-induced angioedema is vital for successful patient outcomes. This report increases awareness of everolimus as a potentially causative agent for the development of angioedema.

4 December 2016 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
KMKatherine L. March
Katherine L. March
KPKruti S. Patel
Kruti S. Patel
JTJennifer D. Twilla
Jennifer D. Twilla
Treatment strategies for acute toxicity following massive ingestion of warfarin are not well described in the literature. Warfarin is the primary oral anticoagulation agent used in the treatment of thromboembolic disease, and patients with acute toxicity are at risk for life-threatening hemorrhages. Treatment options include phytonadione (vitamin K1), fresh frozen plasma (FFP), and prothrombin complex concentrates (PCCs) used alone or in combination. FFP and PCC can be associated with volume complications, undesirable thromboembolic events, and increased costs. We describe the case of a 63-year-old female with acute warfarin toxicity following a massive ingestion of warfarin (420 mg–450 mg) in an attempt to commit suicide. Upon arrival to the emergency department, serial INR checks were initiated to help guide dosing strategy and later adjusted based on INR response to treatment using only phytonadione.